Aprea Therapeutics Reports Q3 Financials and Advances in Clinical Trials

Aprea Therapeutics

DOYLESTOWN, PAAprea Therapeutics, Inc. (Nasdaq: APRE) released its third-quarter financial results for 2024, reporting key advancements in its clinical-stage therapeutic candidates. The company is making significant strides in the development of its WEE1 inhibitor, APR-1051, and ATR inhibitor, ATRN-119, alongside bolstering its team with the appointment of Dr. Philippe Pultar as a senior medical advisor.

Aprea’s Phase 1 ACESOT-1051 trial is progressing ahead of schedule, evaluating the WEE1 inhibitor APR-1051, which has shown promise in treating cancers with Cyclin E over-expression. Preliminary findings displayed no unexpected toxicities, bolstering confidence in its potential best-in-class status. Concurrently, the Phase 1/2a ABOYA-119 study is assessing ATRN-119 for patients with DDR-related gene mutations, a category of cancer with high unmet needs.

Operational enhancements include the engagement of Dr. Philippe Pultar, an experienced oncology executive, to guide the advancement of APR-1051. Dr. Pultar’s expertise, particularly in the strategy and execution of oncology programs, is expected to drive forward Aprea’s clinical objectives.

Financially, Aprea ended the quarter with cash reserves of $26.2 million, ensuring sufficient runway for at least the next twelve months. The company reported a net loss of $3.8 million, compared to a $3.2 million loss in the same quarter last year, reflecting increased investments in clinical development.

Research and development expenses rose to $2.8 million, driven by ongoing trials and personnel investments, while general and administrative costs saw a slight decline to $1.6 million, attributed to reduced insurance expenses.

Aprea’s continued focus on advancing its pipeline underscores its commitment to developing transformative cancer therapies, with expectations of releasing further trial data in 2025.

READ:  Trevena, Inc. Navigates Financial Challenges and Strategic Changes

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.